Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy.

Details

Serval ID
serval:BIB_B3369B527251
Type
Article: article from journal or magazin.
Collection
Publications
Title
Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy.
Journal
Journal of virology
Author(s)
Hendel-Chavez H., de Goër de Herve M.G., Giannesini C., Mazet A.A., Papeix C., Louapre C., Chardain A., Boutarfa N., Théaudin M., Adams D., Gasnault J., Stankoff B., Taoufik Y.
ISSN
1098-5514 (Electronic)
ISSN-L
0022-538X
Publication state
Published
Issued date
05/2013
Peer-reviewed
Oui
Volume
87
Number
10
Pages
6055-6059
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Abstract
Progressive multifocal leukoencephalopathy (PML) is the main adverse effect of natalizumab. Detectable JC virus-specific effector memory T-cell (TEM) responses may indicate ongoing JCV replication. We detected JCV-specific TEM responses in blood of patients with multiple sclerosis (MS) treated with natalizumab, including 2 patients with PML. The frequency of detection of these responses increased with the time on natalizumab. Thus, a subset of MS patients exhibit immunological hallmarks of JCV replication during prolonged natalizumab therapy.

Keywords
Adult, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Biological Products/administration & dosage, Biological Products/adverse effects, Female, Humans, Immunologic Factors/administration & dosage, Immunologic Factors/adverse effects, JC Virus/immunology, JC Virus/physiology, Middle Aged, Multiple Sclerosis/drug therapy, Multiple Sclerosis/immunology, Multiple Sclerosis/virology, Natalizumab, T-Lymphocytes/immunology, Virus Replication
Pubmed
Web of science
Open Access
Yes
Create date
12/12/2017 17:30
Last modification date
20/08/2019 15:21
Usage data